Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2667654rdf:typepubmed:Citationlld:pubmed
pubmed-article:2667654lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:2667654lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:2667654lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:2667654lifeskim:mentionsumls-concept:C0085533lld:lifeskim
pubmed-article:2667654pubmed:issue3lld:pubmed
pubmed-article:2667654pubmed:dateCreated1989-9-13lld:pubmed
pubmed-article:2667654pubmed:abstractText399 patients with early breast cancer were randomly allocated to treatment by either modified radical mastectomy or lumpectomy and radiotherapy. 169 had histologically involved axillary nodes and were randomised to receive either adjuvant cytotoxic chemotherapy (76 patients) or no systemic adjuvant treatment (93 patients). Chemotherapy comprised a combination of oral cyclophosphamide and intravenous methotrexate and 5-fluorouracil (CMF) for 12 cycles over one year. Patients in the mastectomy group received a significantly higher percentage of the planned chemotherapy dose compared with those in the radiotherapy group (median 85% v. 71% p less than 0.05). Patients treated with radiotherapy were more frequently nauseated and developed more severe alopecia, but these differences were not statistically significant. At median follow-up of 37 months the relapse-rate and pattern of relapse were similar in both groups of patients receiving CMF.lld:pubmed
pubmed-article:2667654pubmed:languageenglld:pubmed
pubmed-article:2667654pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2667654pubmed:citationSubsetIMlld:pubmed
pubmed-article:2667654pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2667654pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2667654pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2667654pubmed:statusMEDLINElld:pubmed
pubmed-article:2667654pubmed:monthJullld:pubmed
pubmed-article:2667654pubmed:issn0167-6806lld:pubmed
pubmed-article:2667654pubmed:authorpubmed-author:RubensR DRDlld:pubmed
pubmed-article:2667654pubmed:authorpubmed-author:HaywardJ LJLlld:pubmed
pubmed-article:2667654pubmed:authorpubmed-author:TonoLLlld:pubmed
pubmed-article:2667654pubmed:authorpubmed-author:WinterP JPJlld:pubmed
pubmed-article:2667654pubmed:authorpubmed-author:FentimanI SISlld:pubmed
pubmed-article:2667654pubmed:authorpubmed-author:ChaudaryM AMAlld:pubmed
pubmed-article:2667654pubmed:authorpubmed-author:HabibollahiFFlld:pubmed
pubmed-article:2667654pubmed:authorpubmed-author:DoranZZlld:pubmed
pubmed-article:2667654pubmed:issnTypePrintlld:pubmed
pubmed-article:2667654pubmed:volume13lld:pubmed
pubmed-article:2667654pubmed:ownerNLMlld:pubmed
pubmed-article:2667654pubmed:authorsCompleteYlld:pubmed
pubmed-article:2667654pubmed:pagination237-41lld:pubmed
pubmed-article:2667654pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:meshHeadingpubmed-meshheading:2667654-...lld:pubmed
pubmed-article:2667654pubmed:year1989lld:pubmed
pubmed-article:2667654pubmed:articleTitleInfluence of radiotherapy on the dose of adjuvant chemotherapy in early breast cancer.lld:pubmed
pubmed-article:2667654pubmed:affiliationICRF Clinical Oncology Unit, Guy's Hospital, London, United Kingdom.lld:pubmed
pubmed-article:2667654pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2667654pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2667654pubmed:publicationTypeRandomized Controlled Triallld:pubmed